Cmv virus effects on the immune system in kidney transplant
Treatments studied
Part of Infections clinical trials.
This study looks at how CMV (a common virus) affects the immune system in kidney transplant patients. It may help doctors better manage CMV after transplant and improve transplant outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You are either waiting for a kidney transplant from a living donor, or you already received a kidney transplant and have CMV (a common virus) in your blood.
- You must not have an active infection (other than CMV) at the time you join.
- If you are waiting for a transplant, you must not be on a desensitization protocol (a treatment to reduce anti-transplant antibodies).
- You cannot be under legal guardianship or protection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.